Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exidavnemab in Parkinson's Disease and Multiple System Atrophy
NCT06671938Phase 2Completed
- Sponsor
- BioArctic
- Start
- Oct 2024
- Primary completion
- Aug 2026
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) and multiple system atrophy (MSA) comparing exidavnemab with Placebo (2 arms). Primary endpoint: Number of participants with adverse events (AEs) and serious adverse events (SAEs) at Day 176. Started Oct 2024; status: completed.
02
Drugs
exidavnemab
03
Conditions
Parkinson's disease (PD)multiple system atrophy (MSA)
Beyond the preview
Go deeper on NCT06671938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06671938.